Faeth Therapeutics Inc. has reported preliminary Phase 2 topline results for PIKTOR plus paclitaxel in advanced endometrioid endometrial cancer, with a confirmed objective response rate of 33% among 36 efficacy-evaluable patients whose tumours carried alterations in the PI3K/AKT/mTOR pathway. Among 16 patients with PIK3CA mutations, the confirmed response rate reached 44%, while preliminary median progression-free survival across all 42 treated patients was 7.4 months.
The November 9 readout gave Faeth enough evidence to say it intends to advance PIKTOR towards a Phase 3 registrational study, subject to regulatory alignment. The company has already secured U.S. Food and Drug Administration Fast Track designation for PIKTOR plus paclitaxel in advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations following platinum chemotherapy and an immune checkpoint inhibitor.
Investors nevertheless delivered a strikingly different assessment. Faeth shares closed at $12.68 on November 9, down about 42.5% from $22.05 in the previous session, with trading volume surging above four million shares compared with roughly 535,000 on November 6. The reaction does not establish which individual part of the dataset disappointed investors, but it shows that a 33% response rate and 7.4-month preliminary median progression-free survival did not resolve concerns around efficacy magnitude, safety or the path to a competitive Phase 3 programme.
What did the PIK-201 Phase 2 study actually show in advanced endometrial cancer?
PIK-201 is an open-label, single-arm Phase 2 study evaluating PIKTOR, Faeth’s combination of serabelisib and sapanisertib, with paclitaxel in patients with advanced endometrioid endometrial cancer carrying a PI3K/AKT/mTOR pathway mutation. The trial is being conducted with The GOG Foundation and had treated 42 patients at the October data cutoff.
Patients were heavily pretreated. They had received a median of two previous therapy lines, with 36% having received three or more, while all 42 patients had previously received taxane-based chemotherapy and 98% had undergone prior immunotherapy. Distant metastatic disease involving sites including the liver and lungs was present in 76% of the treated population.
Six of the 42 patients were not evaluable for tumour response because they discontinued before the first post-baseline scan, including three because of early disease progression and three for reasons not attributed to treatment. Among the remaining 36 efficacy-evaluable patients, 12 achieved confirmed objective responses, producing the reported 33% confirmed response rate.
One additional patient achieved a partial response but discontinued before a confirmatory scan, taking the unconfirmed response rate to 36%. The distinction matters because the headline 33% reflects confirmed responses rather than combining responses that had not yet satisfied confirmation requirements.
Why does the 44% response rate in PIK3CA-mutated tumours deserve attention but not overinterpretation?
Among the 16 efficacy-evaluable patients whose tumours carried a PIK3CA mutation, seven achieved a confirmed response, producing a 44% response rate. That is directionally interesting because serabelisib selectively inhibits PI3K-alpha, the protein encoded by PIK3CA, giving the subgroup result biological relevance to PIKTOR’s mechanism.
The subgroup is nevertheless small. Seven responders among 16 patients can generate an eye-catching percentage, but several additional patients responding or failing to respond in a larger population could materially shift that estimate. The current results therefore support further investigation of PIK3CA as a potential response-enriching biomarker but do not validate PIK3CA-mutated endometrial cancer as a definitively proven treatment population.
Faeth’s broader Phase 3 strategy will need to decide how tightly to define biomarker eligibility. Restricting enrollment to a narrower molecular subgroup could potentially enrich treatment effect, while broadening eligibility across different PI3K/AKT/mTOR alterations could create a larger commercial population but increase biological heterogeneity.
The FDA Fast Track designation currently applies to patients whose tumours harbour a PI3K/AKT/mTOR pathway alteration rather than only PIK3CA mutations. Phase 3 trial design and regulatory discussions will therefore be important in determining whether the PIK3CA signal changes the intended population.
Does 7.4 months of median progression-free survival strengthen the case for Phase 3?
Across all 42 treated patients, preliminary Kaplan-Meier estimated median progression-free survival was 7.4 months, with a 95% confidence interval extending from 5.3 months to not reached. The estimated six-month progression-free survival rate was 62%, and 16 patients remained on treatment at the October 30 efficacy cutoff.
Nine of the 12 confirmed responders remained on treatment, together with seven patients whose best response was stable disease. Faeth also reported that some responses deepened over time, including one patient who moved from stable disease to a partial response after approximately 20 months of therapy.
Those durability observations strengthen the early efficacy narrative because a short-lived tumour response would be less compelling in a chronic treatment strategy. The dataset remains immature, however, and median progression-free survival is still preliminary because several patients continue treatment and follow-up.
Faeth has compared its results favourably with historical outcomes from salvage chemotherapy and newer treatments, but such comparisons cannot establish superiority. Differences in tumour subtype, molecular eligibility, previous therapies, response assessment and patient characteristics make a randomized Phase 3 comparator essential before PIKTOR’s relative clinical value can be established.
Why is multi-node PI3K and mTOR inhibition central to Faeth’s PIKTOR strategy?
PIKTOR combines serabelisib, a selective PI3K-alpha inhibitor, with sapanisertib, an inhibitor of both mTORC1 and mTORC2. Faeth’s development thesis is that targeting multiple points in the PI3K/AKT/mTOR signalling network may produce deeper pathway suppression than blocking a single component.
The biological reasoning stems from the ability of cancer signalling networks to adapt. Inhibiting one node can trigger feedback signalling or alternative pathway activation, potentially allowing tumour cells to restore downstream signalling and develop resistance. PIKTOR is designed to suppress this compensatory behaviour by inhibiting PI3K-alpha and mTOR signalling simultaneously.
This is a mechanistic hypothesis rather than a demonstrated clinical advantage over single-node inhibitors. The Phase 2 data show that the combination has antitumour activity in molecularly selected endometrial cancer, but a single-arm study cannot determine whether the multi-node architecture itself produces better outcomes than another pathway-directed strategy.
The combination also introduces a safety challenge because inhibiting several components of an important metabolic signalling pathway can increase biological effects outside the tumour. That issue becomes central when examining the PIK-201 adverse-event profile.
Why does the 64% rate of Grade 3 or higher treatment-related adverse events matter?
Faeth reported that 64% of the 42 treated patients experienced a Grade 3 or higher treatment-related adverse event. Neutropenia, including decreased neutrophil counts, was the most frequent severe treatment-related toxicity, occurring at Grade 3 or higher in 26% of patients.
The overall treatment-related neutropenia rate was 36%, meaning more than one-third of the study population experienced some degree of this toxicity. Paclitaxel itself can cause myelosuppression, and because PIK-201 evaluates PIKTOR in combination with paclitaxel, the single-arm design does not allow the contribution of each component to be separated reliably.
Two patients, or 5%, discontinued treatment because of treatment-related adverse events, involving headache and dizziness. Faeth reported no treatment-related deaths at the October 23 safety cutoff, providing some reassurance that severe toxicity had not translated into treatment-attributed mortality within the disclosed population.
The 64% figure does not mean the regimen is necessarily unsuitable for further development, particularly in heavily treated advanced cancer. It does mean Phase 3 development will need to demonstrate that the clinical benefit is large enough to justify the adverse-event burden and that dose management, supportive care and treatment discontinuations remain workable in a broader population.
What do hyperglycaemia and stomatitis reveal about the tolerability of pathway inhibition?
Hyperglycaemia is a recognised concern with inhibition of the PI3K/AKT/mTOR pathway because the pathway has important roles in insulin signalling and glucose metabolism. In PIK-201, treatment-related hyperglycaemia occurred in five of 42 patients, or 12%, with one Grade 3 event.
The baseline population makes the result particularly interesting because 48% of patients had diabetes or prediabetes before entering the trial. Faeth highlighted the relatively modest reported hyperglycaemia rate despite that metabolic vulnerability, although the small sample and preliminary nature of the dataset mean larger studies will be required to establish how easily glucose abnormalities can be managed.
Treatment-related stomatitis occurred in 21% of patients, with one Grade 3 event. Patients did not receive prophylactic steroid mouthwash, which Faeth cited as part of its tolerability interpretation.
These specific toxicities appear less prominent than might be feared from multi-node pathway inhibition, but focusing only on hyperglycaemia and stomatitis would understate the overall safety picture. The 64% Grade 3 or higher treatment-related adverse-event rate, driven in part by neutropenia, remains the more consequential number when considering how a Phase 3 trial must balance efficacy against toxicity.
Why did Faeth shares collapse despite management calling the data positive?
Faeth shares closed at $12.68 on November 9 after ending the previous session at $22.05, representing a decline of about 42.5%. The stock traded as low as approximately $10.45 during the session, while volume rose to roughly 4.05 million shares, many times the level recorded on the preceding trading day.
The market reaction coincided with publication of the PIK-201 results, but it should not automatically be reduced to one disputed number. Investors may have weighed the response rate, the absence of a randomized comparator, the 64% severe treatment-related adverse-event rate, uncertainty over Phase 3 design and expectations already embedded in the stock price before the readout.
Faeth shares had risen from $19.23 on November 2 to $22.05 by November 6, meaning anticipation had built ahead of the data. A clinical readout can therefore be scientifically encouraging while still disappointing investors if the results fail to exceed expectations or leave important questions unresolved.
At the November 9 close, Faeth’s market capitalisation had fallen to roughly $327 million, down from about $570 million on November 6. The scale of the decline makes the Phase 2 interpretation strategically important because PIKTOR is the company’s lead development programme.
Does Faeth have enough financial runway to take PIKTOR into a registrational study?
Faeth reported $174.8 million in cash, cash equivalents and marketable securities at September 30, 2026. Research and development spending was $11.7 million during the third quarter, while general and administrative expenses were $10.4 million and the quarterly net loss was $20.4 million.
That cash position gives the company meaningful resources to continue development, but a global registrational oncology study can require substantially greater spending than a 42-patient Phase 2 programme. Manufacturing, clinical-site expansion, biomarker testing and regulatory work could all increase cash requirements as PIKTOR moves towards later-stage development.
The sharp decline in Faeth’s share price also matters because biotechnology companies frequently use equity markets to finance expensive clinical programmes. A lower valuation can make future capital raising more dilutive, even when the underlying company maintains a sizeable current cash balance.
The financing question is therefore connected directly to Phase 3 design. A more focused biomarker population may require fewer patients but create a narrower opportunity, while a broader trial could require considerably more capital and time to produce a registrational result.
Why is FDA Fast Track designation useful without reducing PIKTOR’s evidence burden?
The FDA has granted Fast Track designation to PIKTOR plus paclitaxel for advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations after prior platinum chemotherapy and immune checkpoint inhibitor treatment. The designation can facilitate more frequent regulatory interaction and may allow aspects of a future application to be reviewed on a rolling basis if relevant criteria are met.
Fast Track does not mean PIKTOR is approved, nor does it indicate that the FDA has judged the Phase 2 efficacy sufficient for registration. The therapy remains investigational and Faeth has said advancement into Phase 3 is subject to alignment with regulators.
That regulatory interaction is now the most important near-term milestone for the programme. Faeth needs agreement on patient selection, comparator, endpoints, sample size and statistical assumptions before the Phase 2 dataset can become the foundation of a registrational strategy.
The company will also need to determine how the PIK3CA-mutated subgroup should influence Phase 3 design. A 44% response rate provides a biological clue, but regulators generally require prospectively defined evidence rather than retrospective enthusiasm around the most favourable subgroup.
What must PIKTOR prove in Phase 3 after the market rejected the Phase 2 readout?
PIK-201 has produced enough evidence to justify continued development. A 33% confirmed response rate, 83% disease control rate and preliminary median progression-free survival of 7.4 months in a heavily pretreated molecularly selected population represent a genuine clinical signal rather than a purely pharmacodynamic observation.
The study also leaves substantial uncertainty. It is open label and single arm, six treated patients were not evaluable for response, efficacy data remain preliminary, and Grade 3 or higher treatment-related adverse events occurred in nearly two-thirds of patients. None of those limitations erases the signal, but together they explain why the next study has to be much more rigorous.
The 44% response rate among PIK3CA-mutated tumours may ultimately become one of the most important clues in the dataset if it identifies patients more likely to benefit. Phase 3 will need to show whether that apparent enrichment is reproducible and whether multi-node pathway inhibition improves clinically meaningful outcomes against an appropriate comparator.
Faeth’s 42% share-price collapse makes the development stakes unusually visible. Management sees a dataset strong enough to advance into a registrational trial, while the market has clearly demanded more. Phase 3 now has to determine which interpretation is closer to reality: that PIKTOR represents a differentiated way to attack one of endometrial cancer’s most commonly altered signalling pathways, or that the Phase 2 response signal is not strong enough to outweigh toxicity and competitive uncertainty.
